argenx

• Capital Increase raising USD 1.3 billion on Nasdaq and Euronext Brussels at a premium of 1.1% vis-à-vis the last closing price of ordinary shares ahead of transaction announcement and a tight discount of 3.3% vis-à-vis the last ADS closing price
• The transaction was launched on the back of positive topline data from the ADHERE study of efgartigimod in patients with chronic inflammatory demyelinating polyneuropathy, validating use in the hardest of its >10 pursued indications. The company subsequently announced its Capital Increase after US market close with a 24-hour bookbuild period allowing both US and European investors to participate in the opportunity
• The Capital Increase was upsized from originally USD 750 million due to strong demand, including a pre-launch anchor order of USD 200m from specialist investor Baillie Gifford – who Van Lanschot Kempen was instrumental in onboarding as a key shareholder in 2018-2019
• Van Lanschot Kempen alone generated demand that covered more than the original base deal size and was once more the only European bank in a US banking syndicate on a raise by a (dual-)Nasdaq-listed Life Sciences issuer
• argenx’ fundraise marks the largest Capital Increase for a European biotech company and globally the largest since Moderna raised USD 1.3 billion in 2020 on the promise of its COVID-19 vaccine
• The transaction builds on the long-standing relationship between argenx and Van Lanschot Kempen:
  

In the last twelve months, Van Lanschot Kempen has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

• Joint Bookrunner in the SEK 500m Capital Increase by Vicore Pharma
• Financial Adviser to NewAmsterdam Pharma in the USD 182 million secondary sell-down by existing investors
• Joint Global Coordinator & Joint Bookrunner in the EUR 25 million Capital Increase by Vivoryon Therapeutics 
• Joint Global Coordinator & Joint Bookrunner in the EUR 16 million Capital Increase by Sequana Medical
• Lead Manager in the DKK 1.5 billion Capital Increase by Zealand Pharma
• Capital Markets Advisor & Placement Agent in the merger between European Biotech Acquisition Corp. and Oculis SA and the connected USD 91 million PIPE
• Lead Manager in the USD 250 million US Public Offering by CureVac
• Sole Financial Adviser to GenSight Biologics in securing a €12.0 million credit facility from Heights Capital Management
• Joint Global Coordinator and Joint Bookrunner in the SEK 416 million Capital Increase by Hansa Biopharma
• Sole Financial Adviser in SynAct Pharma’s acquisition of TXP Pharma and Joint Global Coordinator & Joint Bookrunner in SynAct Pharma’s SEK 80 million PIPE
• Joint Bookrunner in the SEK 200 million Accelerated Bookbuild Offering by Vicore Pharma
• Joint Global Bookrunner in the SEK 148 million Fully Guaranteed Rights Issue by Biovica
• Sole Financial Adviser to GenSight Biologics in securing a €35.0 million credit facility from the European Investment Bank 
• Joint Global Coordinator & Joint Bookrunner in the SEK 170 million Accelerated Bookbuild offering of Xbrane Biopharma
• Co-Lead Manager in the DKK 786 million Capital Increase by Zealand Pharma
• Financial Advisor in the sale of Sanquin Reagents by Sanquin Health Solutions to Gilde Healthcare
• Financial Advisor in the up to SEK 250 million (convertible) debt financing by Mendus
• Joint Global Coordinator in the SEK 299 million Directed Share Issue by BioInvent
• Sole Global Coordinator in the SEK 200 million financing consisting of a SEK 150m PIPE and a SEK 50 million Fully Guaranteed Rights Issue by Abliva
• Joint Global Coordinator & Joint Bookrunner in the SEK 150 million Fully Guaranteed Rights Issue by SynAct Pharma